Association between phosphorylated AMP-activated protein kinase and MAPK3/1 expression and prognosis for patients with gastric cancer

Oncology (Switzerland)

Volumn 85, Issue 2, 2013, Pages 78-85

  Kim, Jong Gwang ^a   Lee, Soo Jung ^a   Chae, Yee Soo ^a   Kang, Byung Woog ^a   Lee, You Jin ^a   Oh, Sung Yong ^b   Kim, Min Chan ^b   Kim, Ki Han ^b   Kim, Su Jin ^b  

^a Kyungpook National University Hospital   (South Korea)

^b Dong A University College of Medicine   (South Korea)

Author keywords

AMPK; Gastric cancer; MAPK3 1; Prognostic markers; Resection

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN NUAK2; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; STOMACH ADENOCARCINOMA; TISSUE MICROARRAY;

EID: 84880183847     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000351234     Document Type: Article

References (28)

1. Anderson C, Nijagal A, Kim J: Molecular markers for gastric adenocarcinoma: an update. Mol Diagn Ther 2006; 10: 345-352.
2. Miyahara R, Niwa Y, Matsuura T, Maeda O, Ando T, Ohmiya N, Itoh A, Hirooka Y, Goto H: Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol 2007; 22: 1435-1442.
3. Chen J: Multiple signal pathways in obesityassociated cancer. Obes Rev 2011; 12: 1063-1070.
4. Faulds MH, Dahlman-Wright K: Metabolic diseases and cancer risk. Curr Opin Oncol 2012; 24: 58-61.
5. Zhao Y, Liu H, Riker AI, Fodstad O, Ledoux SP, Wilson GL, Tan M: Emerging metabolic targets in cancer therapy. Front Biosci 2011; 16: 1844-1860.
6. Hardie DG: AMP-Activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem Soc Trans 2011; 39: 1-13.
7. Yun H, Ha J: AMP-Activated protein kinase modulators: a patent review (2006-2010). Expert Opin Ther Pat 2011; 21: 983-1005.
8. Schubbert S, Shannon K, Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7: 295-308.
9. Wang W, Guan KL: AMP-Activated protein kinase and cancer. Acta Physiol (Oxf) 2009; 196: 55-63.
10. Fay JR, Steele V, Crowell JA: Energy homeostasis and cancer prevention: the AMP-Activated protein kinase. Cancer Prev Res (Phila) 2009; 2: 301-309.
11. Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS, Ogino S: Prognostic significance of AMP-Activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer 2010; 103: 1025-1033.
12. Buckendahl AC, Budczies J, Fiehn O, Darb-Esfahani S, Kind T, Noske A, Weichert W, Sehouli J, Braicu E, Dietel M, Denkert C: Prognostic impact of AMP-Activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics. Oncol Rep 2011; 25: 1005-1012.
13. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG, Fleming S, Thompson AM: Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 2009; 9: 307.
14. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar D, Brown ML, Fornace A, Dritschil A, Collins SP: AMP-Activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 2009; 8: 733-741.
15. Yu SY, Chan DW, Liu VW, Ngan HY: Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-Activated protein kinase. Tumour Biol 2009; 30: 80-85.
16. William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, Wistuba II, Lee HY: The impact of phosphorylated AMP-Activated protein kinase expression on lung cancer survival. Ann Oncol 2012; 23: 78-85.
17. Hamilton SR, Aaltonen LA: WHO Classification. Tumours of the Digestive System: Pathology & Genetics. Lyon, IARC, 2000.
18. Greene FL, Page DL, Fleming ID: The AJCC Cancer Staging Manual, ed 6. New York, Springer, 2002.
19. Shackelford DB, Shaw RJ: The LKB1-AMPK pathway: metabolism and growth control in tumor suppression. Nat Rev Cancer 2009; 9: 563-575.
20. Inoki K, Guan KL: Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Hum Mol Genet 2009; 18:R94-R100.
21. Esteve-Puig R, Canals F, Colome N, Merlino G, Recio JA: Uncoupling of the LKB1-AMPK? energy sensor pathway by growth factors and oncogeneic BRAF. PLoS One 2009; 4:e4771.
22. Kim MJ, Park IJ, Yun H, Kang I, Choe W, Kim SS, Ha J: AMP-Activated protein kinase antagonizes pro-Apoptotic extracellular signal-regulated kinase activation by inducing dual-specificity protein phosphatases in response to glucose deprivation in HCT116 carcinoma. J Biol Chem 2010; 285: 14617-14627.
23. Buzzai SL, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, Viollet B, Thompson CB: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 2007; 67: 6745-6752.
24. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN: The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-Activated protein kinase. Cancer Prev Res (Phila) 2008; 1: 369-375.
25. Ido Y, Carling D, Ruderman N: Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMPactivated protein kinase activation. Diabetes 2002; 51: 159-167.
26. Carretero J, Medina PP, Blanco R, Smit L, Tang M, Roncador G, Maestre L, Conde E, Lopez-Rios F, Clevers HC, Sanchez-Cespedes M: Dysfunctional AMPK activity, signaling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene 2007; 26: 1616-1625.
27. Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Müller V, Löning T: Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 2005; 92: 2206-2215.
28. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG 3rd, Fuller GN, Aldape KD: Prognostic associations of activated mitogen-Activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 2006; 12: 3935-3941.